Skip to main content
. 2012 Mar 9;8:105–130. doi: 10.2147/TCRM.S29830

Table Q.

Adjusted indirect comparison of the proportion of prior nonresponding and prior relapsing patients achieving a sustained virologic response in the boceprevir and telaprevir standard-dose durations

Patients Boceprevir Telaprevir Relative risk (95% CI) P value
Sustained virologic response
Prior nonresponders 8.09 (2.66–24.65) 4.41 (2.52–7.71) 0.54 (0.15–1.89) 0.33
Prior relapsers 2.54 (1.84–3.52) 3.55 (2.61–4.82) 0.71 (0.45–1.11) 0.14

Abbreviation: CI, confidence interval.